Randomized Controlled Phase II Trial Of Neoadjuvant Sorafenib Therapy Prior to Thermal Ablation for Hepatocellular Carcinoma More Than 4 cm in Size.
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms LANEX
- 04 Mar 2017 Status changed from recruiting to completed.
- 03 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
- 17 Jan 2012 New trial record